Apex Biotechnology Corp. (TPE:1733)
Taiwan
· Delayed Price · Currency is TWD 28.70
0.00 (0.00%)
Apr 29, 2026, 1:30 PM CST
Apex Biotechnology Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Market Capitalization | 2,869 | 3,043 | 3,009 | 4,028 | 2,554 | 2,599 | Upgrade
|
| Market Cap Growth | -16.20% | 1.16% | -25.31% | 57.73% | -1.73% | 10.38% | Upgrade
|
| Enterprise Value | 2,335 | 2,594 | 2,667 | 3,842 | 2,337 | 2,292 | Upgrade
|
| Last Close Price | 28.70 | 30.45 | 28.93 | 37.54 | 22.65 | 21.94 | Upgrade
|
| PE Ratio | 17.72 | 18.68 | 23.50 | 34.79 | 14.05 | 12.85 | Upgrade
|
| Forward PE | - | 13.84 | 13.84 | 13.84 | 13.84 | 13.84 | Upgrade
|
| PS Ratio | 1.47 | 1.57 | 1.62 | 2.40 | 1.14 | 1.22 | Upgrade
|
| PB Ratio | 1.53 | 1.63 | 1.65 | 2.24 | 1.41 | 1.48 | Upgrade
|
| P/TBV Ratio | 1.56 | 1.66 | 1.69 | 2.30 | 1.46 | 1.58 | Upgrade
|
| P/FCF Ratio | 19.80 | 21.01 | 10.01 | 19.32 | - | 16.95 | Upgrade
|
| P/OCF Ratio | 17.92 | 19.01 | 9.15 | 17.48 | 95.95 | 14.45 | Upgrade
|
| EV/Sales Ratio | 1.20 | 1.33 | 1.44 | 2.29 | 1.04 | 1.08 | Upgrade
|
| EV/EBITDA Ratio | 11.64 | 13.59 | 14.65 | 18.60 | 8.99 | 7.86 | Upgrade
|
| EV/EBIT Ratio | 16.59 | 18.44 | 20.76 | 27.11 | 13.24 | 11.18 | Upgrade
|
| EV/FCF Ratio | 16.12 | 17.91 | 8.88 | 18.43 | - | 14.95 | Upgrade
|
| Debt / Equity Ratio | 0.06 | 0.06 | 0.07 | 0.09 | 0.10 | 0.16 | Upgrade
|
| Debt / EBITDA Ratio | 0.55 | 0.55 | 0.64 | 0.71 | 0.67 | 0.95 | Upgrade
|
| Debt / FCF Ratio | 0.76 | 0.76 | 0.41 | 0.74 | - | 1.86 | Upgrade
|
| Net Debt / Equity Ratio | -0.29 | -0.29 | -0.26 | -0.16 | -0.12 | -0.19 | Upgrade
|
| Net Debt / EBITDA Ratio | -2.80 | -2.80 | -2.61 | -1.41 | -0.83 | -1.17 | Upgrade
|
| Net Debt / FCF Ratio | -3.69 | -3.69 | -1.58 | -1.39 | 21.76 | -2.22 | Upgrade
|
| Asset Turnover | 0.80 | 0.80 | 0.79 | 0.70 | 0.87 | 0.80 | Upgrade
|
| Inventory Turnover | 2.30 | 2.30 | 1.89 | 1.54 | 2.44 | 2.75 | Upgrade
|
| Quick Ratio | 2.53 | 2.53 | 2.00 | 1.93 | 1.57 | 1.42 | Upgrade
|
| Current Ratio | 3.87 | 3.87 | 3.44 | 3.93 | 2.90 | 2.24 | Upgrade
|
| Return on Equity (ROE) | 8.82% | 8.82% | 7.07% | 6.40% | 10.16% | 11.90% | Upgrade
|
| Return on Assets (ROA) | 3.64% | 3.64% | 3.40% | 3.68% | 4.26% | 4.81% | Upgrade
|
| Return on Invested Capital (ROIC) | 8.95% | 9.00% | 7.53% | 7.49% | 10.65% | 14.91% | Upgrade
|
| Return on Capital Employed (ROCE) | 7.10% | 7.10% | 6.60% | 7.40% | 9.10% | 10.90% | Upgrade
|
| Earnings Yield | 5.68% | 5.35% | 4.25% | 2.87% | 7.12% | 7.78% | Upgrade
|
| FCF Yield | 5.05% | 4.76% | 9.99% | 5.18% | -0.39% | 5.90% | Upgrade
|
| Dividend Yield | 4.53% | 4.27% | 4.15% | 2.93% | 6.18% | 5.93% | Upgrade
|
| Payout Ratio | 73.63% | 73.63% | 85.90% | 120.86% | 71.48% | 54.06% | Upgrade
|
| Buyback Yield / Dilution | -0.15% | -0.15% | -0.08% | 0.34% | 4.70% | 6.53% | Upgrade
|
| Total Shareholder Return | 4.42% | 4.12% | 4.07% | 3.27% | 10.88% | 12.46% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.